Key Highlights

  • On June 23, 2026, Germany's BfArM approved without conditions Silexion's Clinical Trial Application for a Phase 2/3 study of SIL204 in locally advanced pancreatic cancer, backed by a positive Ethics Committee opinion.
  • Combined with Israel's March 24, 2026 authorization, Silexion can now proceed toward first patient dosing, expected "in the coming weeks."
  • SIL204 remains untested in humans; predecessor LODER only reached a Phase 2a trial showing "a positive trend" versus chemotherapy alone, not a proven survival benefit.
  • Silexion held $2.4 million in cash as of March 31, 2026, down from $6.0 million at year-end 2025, carries going-concern language in its latest 10-Q, and has executed two reverse share splits in the past year.

Silexion Therapeutics Corp. (NASDAQ:SLXN) said on June 23, 2026, that Germany's federal drug regulator, BfArM, unconditionally approved its clinical trial application for a Phase 2/3 study of SIL204 in locally advanced pancreatic cancer, backed by a positive ethics opinion. The clearance follows Israeli authorization in March, but the RNAi candidate has not yet been dosed in a human patient.

Why a German Regulatory Nod Is Moving Silexion (SLXN) Stock

Silexion Therapeutics Corp. (SLXN) is a small clinical-stage biotech built on one thesis: RNA interference, delivered into a solid tumor, can silence the mutated KRAS gene driving roughly 90% of pancreatic cancers. That thesis has generated headlines for decades without an approved therapy, so any regulatory validation draws outsized attention to a company this size.

The news came on June 23, 2026, when Silexion said Germany's Federal Institute for Drugs and Medical Devices (BfArM) had approved its Clinical Trial Application for a Phase 2/3 study of SIL204 in locally advanced pancreatic cancer. The approval was unconditional, with both Part I and Part II of the assessment "determined to be justifiable," alongside a positive opinion from the Ethics Committee of the North Rhine Medical Association, under Articles 5 and 8 of EU Regulation No. 536/2014, with Germany as Reporting Member State for the EU-wide scientific assessment.

To be precise: BfArM's action is a trial-application clearance, not a marketing approval, and says nothing about whether SIL204 works in humans; no patient has yet been dosed. Germany's regulator concluded that the trial design and Silexion's preclinical and toxicology package justify testing SIL204 in people: a meaningful gate, but permission to test, not evidence of a cure.

A Single-Asset RNAi Company Chasing a Two-Decade-Old Target

Silexion's roots trace to Israeli biotech Silenseed, and its science centers on KRAS, an oncogene that has frustrated drug developers for more than 30 years without a single approved KRAS-targeted RNAi therapy. Its approach uses siRNA embedded in a polymer microparticle that releases the drug slowly near the tumor.

The earlier, first-generation candidate, LODER, reached a Phase 2a trial Silexion describes as showing "a positive trend" versus chemotherapy alone (modest language, short of a proven survival benefit. SIL204, the second-generation successor, is designed for broader KRAS-mutation coverage; preclinical data disclosed in September 2025 reported growth inhibition across eight KRAS mutations and four cancer types in human cell lines, plus reduced tumor growth and metastatic spread in animal models) laboratory results, not human data. The cleared Phase 2/3 study pairs an 18-patient safety run-in with a roughly 166-patient randomized expansion, testing SIL204 alongside chemotherapy via a dual intratumoral-and-systemic delivery strategy.

Silexion reached Nasdaq through a de-SPAC merger with Moringa Acquisition Corp (formerly Biomotion Sciences); the combined shares and warrants began trading as SLXN and SLXNW on August 16, 2024.

Clinical Momentum Has Outpaced Financial Stability

Regulatory progress in 2026 has been sequential: Israeli approval March 24; German CTA submission April 28, informed by BfArM Scientific Advice from December 2025; GMP manufacturing with Catalent and a Tel Aviv Sourasky site approval in May; and the June 23 BfArM clearance. Management expects first-patient dosing "in the coming weeks."

Financially, Silexion remains pre-revenue and cash-burning. First-quarter 2026 net loss was approximately $2.7 million, up from $1.7 million a year earlier, as R&D rose to $1.4 million from $0.6 million on toxicology and manufacturing costs, while G&A rose to $1.4 million from $1.1 million. Full-year 2025 net loss was $11.9 million, improved from $16.5 million in 2024, on R&D of $7.1 million and G&A of $4.5 million.

Cash Is Thin, and Going-Concern Language Persists

Silexion ended the first quarter of 2026 with $2.4 million in cash, down from $6.0 million at December 31, 2025, after negative operating cash flow of $3.6 million. Shareholders' equity fell to about $291,000 as of March 31, from $2.6 million three months earlier. The 10-Q for that quarter, filed May 15, 2026, discloses that management believes current funds will last only "several months," raising substantial doubt about the company's ability to continue as a going concern absent additional financing.

Silexion has repeatedly returned to markets to bridge that gap, raising over $18.6 million in aggregate gross proceeds during 2025, after which Nasdaq confirmed in September 2025 that the company had regained listing compliance. Since quarter-end it closed a roughly $1.0 million warrant-exercise inducement and drew on an at-the-market facility, restoring equity above the $2.5 million Nasdaq minimum. It has also executed two reverse splits within about a year: 1-for-15 in July 2025, and 1-for-10 effective May 29, 2026, aimed at Nasdaq's bid-price rule (Listing Rule 5550(a)(2)): a pace signaling sustained dilution pressure.

What Comes Next

The near-term catalyst is first patient dosing, guided for "the coming weeks" at sites led by Sheba Medical Center and Tel Aviv Sourasky Medical Center in Israel, and at German centers under the EU's CTIS framework; Silexion has flagged possible expansion into other EU states. Further out: completion of the safety run-in, any interim readout, and initiation of the larger randomized cohort: none of which has occurred, and each carrying the ordinary execution risk of multi-site oncology trials.

Risks Specific to a Concentrated, Thinly Capitalized Biotech

Silexion's risk profile is concentrated: one clinical-stage asset advancing toward human dosing, with prospects entirely dependent on years of additional trials. Cash of $2.4 million against multi-million-dollar quarterly losses makes further dilutive capital raises likely before Phase 2/3 data emerge, and going-concern language shows financing risk is not hypothetical. A cleared trial application is no guarantee of a positive result, and pancreatic cancer carries one of oncology's lowest five-year survival rates; KRAS has eluded drug developers for three decades, and SIL204 must still prove itself in humans.

Outlook

The upside case: SIL204 completes its safety run-in and advances into the randomized cohort with acceptable tolerability, validating years of preclinical work in a disease with substantial unmet need. The base case: a lengthy, capital-intensive multi-year oncology trial process requiring repeated financing, with results not expected soon after dosing begins. The downside case: financing difficulty, delays, or unfavorable early signals pressuring a company whose cash is already thin relative to its burn rate. This article predicts nothing about SIL204's clinical outcome or Silexion's share price; the clearances mark the start of testing, not proof RNAi has solved KRAS-driven cancer.

Conclusion

Silexion Therapeutics Corp. (SLXN) has cleared a genuine regulatory hurdle: unconditional BfArM authorization, alongside Israeli approval, to begin dosing SIL204 in a Phase 2/3 pancreatic-cancer trial. That is a real milestone for a small RNAi biotech pursuing one of oncology's hardest targets. It is not evidence the drug works in humans, and it arrives alongside a $2.4 million cash position, going-concern disclosure, and a history of dilutive financing investors should weigh alongside the clinical narrative.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.